Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bionetide - Biomed Industries

Next Previous
Search
Drug Profile

Bionetide - Biomed Industries

Alternative Names: NA-921

Latest Information Update: 31 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biomed Industries
  • Class Neuroprotectants; Obesity therapies; Small molecules
  • Mechanism of Action Glucagon-like peptide 1 modulators; Insulin-like growth factor I modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Obesity; Rett syndrome

Most Recent Events

  • 15 Feb 2025 Phase-III clinical trials in Obesity (In children, In adolescents, In adults) in Australia, USA (PO) (NCT06840496)
  • 15 Feb 2025 Phase-III clinical trials in Rett syndrome (In adolescents, In children, In adults) in Australia, USA (PO) (NCT06840496)
  • 28 Jan 2025 Biomed Industries completes a phase II/III trial in Rett syndrome (In Children, In adolescent, In adults) in USA, Australia (PO, Liquid) (NCT06849973)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top